Impact of Ketoflex 12/3 Diet on Early-to-Mid Stage Alzheimer's Progression
NCT ID: NCT06898424
Last Updated: 2025-04-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2024-03-01
2024-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Ketogenic Diet in the Treatment of Alzheimer's Disease
NCT06681948
Modified Ketogenic Diet in Amnestic Mild Cognitive Impairments
NCT06444568
The Ketogenic Diet for Alzheimer's Disease
NCT04701957
Feasibility and Efficacy of the Ketogenic Diet in Alzheimer's Disease
NCT03690193
Evaluating Cognitive and Functional Impairment in Alzheimer's Dementia With a Ketogenic Diet.
NCT04396015
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ketoflex 12/3 Diet Group
Participants follow the Ketoflex 12/3 dietary protocol.
Ketoflex 12/3 Diet
plant-based ketogenic diet combined with intermittent fasting (12/3)
Control Group
Participants continue their usual diet with no modifications
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ketoflex 12/3 Diet
plant-based ketogenic diet combined with intermittent fasting (12/3)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical Dementia Rating (CDR) score of 0.5 or 1
* Diagnosis of Alzheimer's disease (AD) according to NINCDS-ADRDA criteria
Exclusion Criteria
* Diagnosis of chronic renal failure
* Diagnosis of another neuropsychiatric disorder
* Presence of amalgam dental fillings and/or failure to have them removed following the SMART protocol
50 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Prof. Lutfu Hanoglu, MD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Lutfu Hanoglu, MD
Prof. MD
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Lütfü Hanoğlu, Prof. MD
Role: PRINCIPAL_INVESTIGATOR
Medipol University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Istanbul Medipol Universitesi
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ALZ23992
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.